ArticleMolecular & cellular proteomics : MCP2013
Proteomic identification of novel secreted antibacterial toxins of the Serratia marcescens type VI secretion system.
Article in Molecular & cellular proteomics : MCP, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 99 citations in OpenAlex.
- Functional diversity of accessory factors of the type VI secretion system.Journal of bacteriology · 2026Review
- Serlogical, virulence, and molecular characterization of clinical and seafoodMicrobiology spectrum · 2026Article
- Tvp complexes support formation of the VgrG-PAAR spike during Type VI secretion system assembly.The EMBO journal · 2026Article
- Investigating bioactive potential of the Serratia sp. CS01 and its pigment for anti-inflammatory, antioxidant and antibacterial action.Scientific reports · 2026Article
- Prevalence and activity of class II microcins inApplied and environmental microbiology · 2026Article
- Complete genome sequence ofMicrobiology resource announcements · 2025Article
- A widely-occurring family of pore-forming effectors broadens the impact of the Serratia Type VI secretion system.The EMBO journal · 2025Article
- Comprehensive genomic analysis of type VI secretion system diversity and associated proteins inMicrobial genomics · 2025Article
- A new class of type VI secretion system effectors can carry two toxic domains and are recognized through the WHIX motif for export.PLoS biology · 2025Article
- Identification of Effectors: Precipitation of Supernatant Material.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Bioprospecting of serratiopeptidase-producing bacteria from different sources.Frontiers in microbiology · 2024Article
- Quantitative Determination of Antibacterial Activity During Bacterial Coculture.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Regulation of type VI secretion systems at the transcriptional, posttranscriptional and posttranslational level.Microbiology (Reading, England) · 2023Review
- PandemicLife science alliance · 2023Article
- Type VI Secretion Systems: Environmental and Intra-host Competition of Vibrio cholerae.Advances in experimental medicine and biology · 2023Article
- Transcriptional organization and regulation of theMicrobiology (Reading, England) · 2023Article
- The structure of a tautomerase superfamily member linked to the type VI secretion system of Acinetobacter baumannii.Acta crystallographica. Section F, Structural biology communications · 2023Article
- Subcellular localization of Type VI secretion system assembly in response to cell-cell contact.The EMBO journal · 2022Article
- PsrA is a novel regulator contributes to antibiotic synthesis, bacterial virulence, cell motility and extracellular polysaccharides production in Serratia marcescens.Nucleic acids research · 2022Article
- Contact-independent killing mediated by a T6SS effector with intrinsic cell-entry properties.Nature communications · 2021Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
It has recently become apparent that the Type VI secretion system (T6SS) is a complex macromolecular machine used by many bacterial species to inject effector proteins into eukaryotic or bacterial cells, with significant implications for virulence and interbacterial competition. "Antibacterial" T6SSs, such as the one elaborated by the opportunistic human pathogen, Serratia marcescens, confer on the secreting bacterium the ability to rapidly and efficiently kill rival bacteria. Identification of secreted substrates of the T6SS is critical to understanding its role and ability to kill other cells, but only a limited number of effectors have been reported so far. Here we report the successful use of label-free quantitative mass spectrometry to identify at least eleven substrates of the S. marcescens T6SS, including four novel effector proteins which are distinct from other T6SS-secreted proteins reported to date. These new effectors were confirmed as antibacterial toxins and self-protecting immunity proteins able to neutralize their cognate toxins were identified. The global secretomic study also unexpectedly revealed that protein phosphorylation-based post-translational regulation of the S. marcescens T6SS differs from that of the paradigm, H1-T6SS of Pseudomonas aeruginosa. Combined phosphoproteomic and genetic analyses demonstrated that conserved PpkA-dependent threonine phosphorylation of the T6SS structural component Fha is required for T6SS activation in S. marcescens and that the phosphatase PppA can reverse this modification. However, the signal and mechanism of PpkA activation is distinct from that observed previously and does not appear to require cell-cell contact. Hence this study has not only demonstrated that new and species-specific portfolios of antibacterial effectors are secreted by the T6SS, but also shown for the first time that PpkA-dependent post-translational regulation of the T6SS is tailored to fit the needs of different bacterial species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.